Cancer continues to be one of the major causes of death throughout the developed world, which has led to increased research on effective treatments. Because of this, in the past decade, rapid progress in the field of cancer treatment has been seen. Recent Advances in Cancer Research and Therapy reviews in specific details some of the most effective and promising treatments developed in research centers worldwide. While referencing advances in traditional therapies and treatments such as chemotherapy, this book also highlights advances in biotherapy including research using Interferon and Super Interferon, HecI based and liposome based therapy, gene therapy, and p53 based cancer therapy. There is also a discussion of current cancer research in China including traditional Chinese medicine. Written by leading scientists in the field, this book provides an essential insight into the current state of cancer therapy and treatment.
- Includes a wide range of research areas including a focus on biotherapy and the development of novel cancer therapeutic strategies.
- Formatted for a broad audience including all working in researching cancer treatments and therapies.
- Discusses special traits and results of Chinese cancer research.
Cancer continues to be one of the major causes of death throughout the developed world, which has led to increased research on effective treatments. Because of this, in the past decade, rapid progress in the field of cancer treatment has been seen. Recent Advances in Cancer Research and Therapy reviews in specific details some of the most effective and promising treatments developed in research centers worldwide. While referencing advances in traditional therapies and treatments such as chemotherapy, this book also highlights advances in biotherapy including research using Interferon and Super Interferon, HecI based and liposome based therapy, gene therapy, and p53 based cancer therapy. There is also a discussion of current cancer research in China including traditional Chinese medicine. Written by leading scientists in the field, this book provides an essential insight into the current state of cancer therapy and treatment. Includes a wide range of research areas including a focus on biotherapy and the development of novel cancer therapeutic strategies. Formatted for a broad audience including all working in researching cancer treatments and therapies. Discusses special traits and results of Chinese cancer research.
List of Contributors
Ying Cai Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Xin Cao Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Chi-Hong Chao Department of Molecular and Cellular Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX
Kai-Xian Chen Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Kun Chen Cancer Institute, Zhejiang University, Hangzhou, People’s Republic of China
Yi Chen Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Liang Chu Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China; Washington University in St. Louis, School of Medicine, St. Louis, MO
Jian Ding Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Miao Ding Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Zhen-Yu Ding Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, People’s Republic of China
Qi Dong Cancer Institute, Zhejiang University, Hangzhou, People’s Republic of China
Jing Fan State Key Laboratory of Molecular Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China
Jun-Kai Fan Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Erin M. Goldblatt Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA
Jin-Fa Gu Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Jennifer L. Hsu Department of Molecular and Cellular Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX; Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University and Hospital, Taichung, Taiwan; Asia University, Taichung, Taiwan
He Huang Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Jing-Yu Huang First Affiliated Hospital, Zhengzhou University, Zhengzhou, Henan Province, People’s Republic of China
Wenlin Huang State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, People’s Republic of China
Wen-Lin Huang Cancer Center, Sun Yat-sen University, Guangzhou, People’s Republic of China
Mien-Chie Hung Department of Molecular and Cellular Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX; Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University and Hospital, Taichung, Taiwan; Asia University, Taichung, Taiwan
Hong-Bin Ji Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Jing Jiang State Key Laboratory of Molecular Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences, Beijing, People’s Republic of China
Yu-Juan Jin Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Ronald G. Jubin UMDNJ-Robert Wood Johnson Medical School, Department of Molecular Genetics Microbiology and Immunology, Piscataway, NJ
Doranelly H. Koltchev UMDNJ-Robert Wood Johnson Medical School, Department of Molecular Genetics Microbiology and Immunology, Piscataway, NJ
Eva Lee Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA
Wen-Hwa Lee Department of Biological Chemistry, School of Medicine, University of California, Irvine, CA
Cui-Ping Li Department of Transfusion, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, People’s Republic of China; Department of Transfusion, the Affiliated BenQ Hospital of Nanjing Medical University, Nanjing, People’s Republic of China
Huang-Guang Li Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Xiao Li Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, People’s Republic of China
Anning Lin Ben May Department for Cancer Research, The University of Chicago, Chicago, IL
Hong Liu Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Hua Liu Cancer Biotherapy Research Laboratory, Zhong Shan Hospital, Fudan University, and Stem Cell Research Laboratory, Min Hang Hospital, Rui Jin Hospital Group, Jiao Tong University, Shanghai, People’s Republic of China
Jing Liu Ben May Department for Cancer Research, The University of Chicago, Chicago, IL; Division of Pulmonary and Critical Care Medicine, Feinberg School of Medicine, Northwestern Univerisity, Chicago, IL
Jing-Yuan Liu Department of Pharmacology and Toxicology and IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN
Leroy F. Liu Department of Pharmacology, UMDNJ-Robert Wood Johnson Medical School and The Cancer Institute of New Jersey, Piscataway, NJ
Lun-Xu Liu Department of Thoracic Surgery, West China Hospital, Chengdu, People’s Republic of China
Qiang Liu Department of Breast Surgery, Sun-Yat-Sen Memorial Hospital, Sun-Yat-Sen University, Guangzhou, People’s Republic of China; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
Xin-Ran Liu Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Xin-Yuan Liu Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, People’s Republic of China; Hui-Yang Life Science and Technology Corp., Chengdu, People’s Republic of China; Xinyuan Institute of Medicine and Biotechnology, College of Life Sciences, Zhejiang Sci-Tech University, Hangzhou, People’s Republic of China
Yao-Hua Liu Department of Pharmacology, Harbin Medical University, Harbin, People’s Republic of China
Xin Lu Ludwig Institute for Cancer Research Oxford Branch, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
You-Yong Lu Laboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital/Institute, Beijing, P.R. China
Xiao-Min Luo Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Yi Lisa Lyu Department of Pharmacology, UMDNJ-Robert Wood Johnson Medical School and The Cancer Institute of New Jersey, Piscataway, NJ
Lin Ma Department of Thoracic Surgery, West China Hospital, Chengdu, People’s Republic of China
Ze-Hong Miao Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, People’s Republic of China
Wei Mo Department of Pharmacology and Toxicology and IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis,...
| Erscheint lt. Verlag | 18.5.2012 |
|---|---|
| Sprache | englisch |
| Themenwelt | Medizin / Pharmazie ► Allgemeines / Lexika |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Studium ► Querschnittsbereiche ► Epidemiologie / Med. Biometrie | |
| Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie | |
| Technik | |
| ISBN-10 | 0-12-397836-X / 012397836X |
| ISBN-13 | 978-0-12-397836-3 / 9780123978363 |
| Haben Sie eine Frage zum Produkt? |
PDF (Adobe DRM)Größe: 31,8 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: PDF (Portable Document Format)
Mit einem festen Seitenlayout eignet sich die PDF besonders für Fachbücher mit Spalten, Tabellen und Abbildungen. Eine PDF kann auf fast allen Geräten angezeigt werden, ist aber für kleine Displays (Smartphone, eReader) nur eingeschränkt geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
EPUB (Adobe DRM)Größe: 10,5 MB
Kopierschutz: Adobe-DRM
Adobe-DRM ist ein Kopierschutz, der das eBook vor Mißbrauch schützen soll. Dabei wird das eBook bereits beim Download auf Ihre persönliche Adobe-ID autorisiert. Lesen können Sie das eBook dann nur auf den Geräten, welche ebenfalls auf Ihre Adobe-ID registriert sind.
Details zum Adobe-DRM
Dateiformat: EPUB (Electronic Publication)
EPUB ist ein offener Standard für eBooks und eignet sich besonders zur Darstellung von Belletristik und Sachbüchern. Der Fließtext wird dynamisch an die Display- und Schriftgröße angepasst. Auch für mobile Lesegeräte ist EPUB daher gut geeignet.
Systemvoraussetzungen:
PC/Mac: Mit einem PC oder Mac können Sie dieses eBook lesen. Sie benötigen eine
eReader: Dieses eBook kann mit (fast) allen eBook-Readern gelesen werden. Mit dem amazon-Kindle ist es aber nicht kompatibel.
Smartphone/Tablet: Egal ob Apple oder Android, dieses eBook können Sie lesen. Sie benötigen eine
Geräteliste und zusätzliche Hinweise
Zusätzliches Feature: Online Lesen
Dieses eBook können Sie zusätzlich zum Download auch online im Webbrowser lesen.
Buying eBooks from abroad
For tax law reasons we can sell eBooks just within Germany and Switzerland. Regrettably we cannot fulfill eBook-orders from other countries.
aus dem Bereich
